Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976571 | 0.84 | LMNA (0.50) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2978223 | 0.83 | TSHR (0.44) | TSHRSMPD1MAOBMAPTL3MBTL1 | |
| SCHEMBL2979742 | 0.79 | HTT (0.56) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2976136 | 0.77 | LMNA (0.46) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL6841050 | 0.74 | CYP17A1 (0.57) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2974579 | 0.74 | LMNA (0.52) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2978980 | 0.73 | LMNA (0.47) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL16539600 | 0.73 | SMN1; SMN2 (0.50) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2981052 | 0.72 | LMNA (0.50) | LMNAHTTSMN1; SMN2MEN1TSHR | |
| SCHEMBL2970130 | 0.72 | LMNA (0.50) | LMNAHTTSMN1; SMN2MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772258-B2 | Agent for treatment of allergic eye disease | NIKKEN CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | NIKKEN CHEMICALS CO., LTD. | 2008-12-11 | — | — | US | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040220227-A1 | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1410795-A1 | REMEDIES FOR ALLERGIC EYE DISEASES | Nikken Chemicals Company, Limited (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220227-A1 | Remedies for allergic eye diseases | HRH2, HRH1, HRH4 | LMNA 3532/4885HTT 3272/4885SMN1; SMN2 4845/4885 |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | HRH4, HRH3, HRH2 | LMNA 4304/4885HTT 2612/4885SMN1; SMN2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.